Savara trial misses primary endpoint, development stopped

 Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc

Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO

Reduces Operating Expenses to Align with Streamlined Development Programs

Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex in aPAP

Revises Study-Start Guidance for IMPALA 2 Clinical Trial to Q2 2021

https://savarapharma.com/investors/press-releases/release/?id=13001